Log in to save to my catalogue

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer...

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6320cb09619d46bdb0b5fd843bc4c5e3

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

About this item

Full title

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

Publisher

London: Nature Publishing Group UK

Journal title

Scientific reports, 2021-03, Vol.11 (1), p.7064-7064, Article 7064

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Triple-negative breast cancer (TNBC) is highly responsive to neoadjuvant polychemotherapy regimens including anthracyclines, taxanes, and, more recently, carboplatin. However, there is inadequate information on the individual contribution of each of these agents to the global activity of the combinations, and the use of combinations of up to four o...

Alternative Titles

Full title

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_6320cb09619d46bdb0b5fd843bc4c5e3

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6320cb09619d46bdb0b5fd843bc4c5e3

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/s41598-021-85962-4

How to access this item